KemPharm Announces Appointment of Christopher Posner as New Independent Director
24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm’s Board of Directors CELEBRATION, Fla., Nov....
24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm’s Board of Directors CELEBRATION, Fla., Nov....
CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in Q1 2024 Context to host...
First Actera™ procedure underscores company’s ongoing commitment to advancing joint replacement technology by leveraging its data-driven approach and surgical planning expertiseBILLERICA,...
Influid Water-soluble Nanotechnology Avicanna's Patent-Pending Influid Technology Inside Viola Water-Soluble THC InfuserDeveloped through Avicanna’s scientific platform, the patent-pending technology provides...
Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant...
– AK006 is an agonistic antibody that targets the mast cell inhibitory receptor Siglec-6 –– AK006 shows deep mast cell...
DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
While Boundary Bay Cannabis Received Demand for Over 725,000 Grams of High-Quality Bulk Cannabis in Just 90 Days, Wholesale Prices...
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company...
Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless...
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage...
Risk scoring by KidneyIntelX resulted in a 4.5-fold increase in new drug prescriptions (for SGLT2 inhibitors) for high risk compared...
CHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...
FDA decision based on new Phase 1b data: Objective Response Rate (ORR) of 57% and median Progression-Free Survival (PFS) of...
--FemaSeed de novo trial enrollment has accelerated with trial recruitment focus on male factor infertility--ATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE)...
Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe illness and faster recovery in...
D-PLEX₁₀₀ Infection Prevention Efficacy in Patients with Increased Risk for Surgical Wound Infections Including Multi-Drug Resistant Organisms (MDROs) will be...
- Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and Co-chair of the Global Business...
SEATTLE, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing...
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- A review published recently in the international scientific journal Biomedicines...